Erectile Dysfunction Treatment Market Report, Share, and Forecast to 2025

Posted by rekha on November 25th, 2019

The Global Erectile Dysfunction Treatment Market is expected to be valued at US$ 2,735.2 Mn by 2025 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to increasing comorbidities with erectile dysfunction, heart diseases, and diabetes”

Precision Business Insights (PBI) in its report titled “Global Erectile Dysfunction Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global erectile dysfunction treatment market is expected to be valued at US$ 2,735.2 Mn by 2025 and growing at a CAGR of 5.9% over the forecast period owing to increasing cases registered on erectile dysfunction coupled with expiry of patents for the major products used for the treatment of erectile dysfunction are anticipated to drive the growth of the market. For instance, Expiry of patent for Viagra in 2012 outside the U.S. has witnessed the launch of various number of generic brands into the market which has increased the sales for the Viagra. Patent expiry of blockbuster brands (molecules), accessibility of other alternatives such as penile implants, penus pumps, ayurvedic medicines are expected to inhibit the growth of the market.

Global erectile dysfunction treatment market segmented on the product, distribution channel, and region.

Request for   sample   report @ https://www.precisionbusinessinsights.com/request-sample?product_id=17273

           

Sildenafil segment accounted for higher revenue share

Based on type, global erectile dysfunction treatment market is segmented Sildenafil [Viagra], Tadalafil [Adcirca, Cialis], Vardenafil [Staxyn, Levitra], Avanafil [Stendra], and Others. Sildenafil segment accounted for the largest market share in 2018 and is expected to grow with highest CAGR over the forecast period owing to increasing demand for sildenafil tablets in the market due to rising prevalence of cases of erectile dysfunction and growing elderly population are anticipated to boost the growth of the market. Launch of new generics by the market players in the market are expected to fuel the growth of the market. For instance, in September 2019, Lupin Pharmaceuticals has launched Sildenafil tablets in various strengths.

Asia Pacific is expected to dominate the market

PBI’s global erectile dysfunction treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, Asia Pacific is expected to grow with highest CAGR over the forecast years owing to increasing prevalence or number of erectile dysfunction cases correlated with diabetes, cardiac problems, and obesity. According to WHO, around 18 Mn men above age 20 are suffering from erectile dysfunction, rising awareness among the patient population regarding the advanced treatments and medications available for the erectile dysfunction is anticipated to drive the growth of the market. Europe and Latin regions market is expected to grow with a significant CAGR over the forecast years.

Recent Developments in the Global Erectile Dysfunction Treatment Market

 

  • In September 2019, Lupin Pharmaceuticals has announced the launch of Sildenafil tablets USP in the strengths of 25 mg, 50 mg, and 100 mg after receiving approval from the United States
  • On 27 March 2017, Vivus receive STENDRA (R) commercial rights from Sanofi, to market in Africa, Middle East, Turkey, and Russia.
  • In February 2019, Dr. Reddy's Laboratories has launched Tadalafil tablets used to treat erectile dysfunction, in the US market.

Key player’s profiles in the report are Pfizer, Inc. (U.S), Bayer AG (Germany), Eli Lilly and Company (U.S), Apricus Biosciences Inc. (U.S), Meda Pharmaceuticals, Inc. (U.S), K. Chemicals Co. Ltd. (Korea), Vivus, Inc. (U.S), and Dong-A ST (South Korea).

Detailed Segmentation

 

By Product

o   Sildenafil [Viagra]

o   Tadalafil [Adcirca, Cialis]

o   Vardenafil [Staxyn, Levitra]

o   Avanafil [Stendra]

o   Others

By Distribution Channel   

o   Hospitals

o   Clinics

o   Others

Geography

 

o     North America

  • U.S
  • Canada

o     Europe

  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

o     Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

o     Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

o     Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 For more information: https://www.precisionbusinessinsights.com/market-reports/global-erectile-dysfunction-treatment-market/

Like it? Share it!


rekha

About the Author

rekha
Joined: July 26th, 2019
Articles Posted: 219

More by this author